Brief: Poseida Therapeutics Presents Positive Early Results From Its Phase 1 Trial Of Allogeneic Car-T P-Bcma-Allo1 In Relapsed-Refractory Multiple Myeloma

Poseida Therapeutics

10/12/2023 17:05

Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS PRESENTS POSITIVE EARLY RESULTS FROM
ITS
PHASE 1 TRIAL OF ALLOGENEIC CAR-T P-BCMA-ALLO1 IN
RELAPSED-REFRACTORY MULTIPLE MYELOMA
    * FAVORABLE EMERGING SAFETY AND RELIABILITY PROFILE, WITH
ALL
(100%) INTENT-TO-TREAT (ITT) PATIENTS RECEIVING THERAPY

Source text for Eikon:  ID:nPnbSfY8Fa 
Further company coverage:  PSTX.O